Brief: Sinovant Sciences And Nabriva Therapeutics Announce Positive Topline Results From Phase 3 Trial Of Lefamulin In Chinese Adults With Community Acquired Bacterial Pneumonia (Cabp)
25/05/2021 23:53
May 25 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* SINOVANT SCIENCES AND NABRIVA THERAPEUTICS ANNOUNCE
POSITIVE
TOPLINE RESULTS FROM PHASE 3 TRIAL OF LEFAMULIN IN CHINESE
ADULTS WITH COMMUNITY ACQUIRED BACTERIAL PNEUMONIA (CABP)
* NABRIVA THERAPEUTICS PLC - LEFAMULIN WAS GENERALLY SAFE
AND
WELL-TOLERATED IN CHINESE ADULTS
* NABRIVA THERAPEUTICS PLC - LEFAMULIN WAS SHOWN TO BE
NON-INFERIOR TO MOXIFLOXACIN
* NABRIVA THERAPEUTICS PLC - GREATER CHINESE RIGHTS TO
LEFAMULIN
WILL BE HELD BY SUMITOMO PHARMACEUTICALS (SUZHOU) CO., LTD.,
Source text for Eikon: ID:nGNXWyJjh
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update